APGE

56.30

3.32% 1.81

Dopo l'orario di chiusura: 56.30

Apogee Therapeutics Inc (APGE)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$54.49

Aprire:

$54.49

Volume 24 ore:

325.82K

Relative Volume:

0.86

Capitalizzazione di mercato:

$3.09B

Reddito:

Utile/perdita netta:

$-118.49M

Rapporto P/E:

EPS:

Flusso di cassa netto:

$-110.57M

1 W Prestazione:

+2.53%

1M Prestazione:

+3.34%

6M Prestazione:

+3.89%

1 anno Prestazione:

+195.07%

Intervallo 1D:

$52.37

$57.01

Intervallo di 1 settimana:

$50.48

$57.01

Portata 52W:

$14.19

$72.29

Apogee Therapeutics Inc Stock (APGE) Company Profile

Nome

Apogee Therapeutics Inc

Settore

Healthcare (1180)

Industria

Biotechnology (680)

Telefono

650-394-5230

Indirizzo

221 CRESCENT ST., WALTHAM

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

APGE's Discussions on Twitter

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-10	Iniziato	BofA Securities	Buy
2023-12-20	Iniziato	BTIG Research	Buy
2023-08-08	Iniziato	Guggenheim	Buy
2023-08-08	Iniziato	Jefferies	Buy
2023-08-08	Iniziato	Stifel	Buy
2023-08-08	Iniziato	TD Cowen	Outperform
2023-08-08	Iniziato	Wedbush	Outperform

Mostra tutto

Apogee Therapeutics Inc Borsa (APGE) Ultime notizie

Nov 04, 2024

Apogee Therapeutics to Participate in Upcoming November Investor Conferences - Marketscreener.com

Nov 04, 2024

Oct 31, 2024

10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey

Oct 31, 2024

Oct 27, 2024

(APGE) Investment Analysis and Advice - Stock Traders Daily

Oct 27, 2024

Oct 25, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 25, 2024

Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

Oct 25, 2024

Oct 24, 2024

Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan

Oct 24, 2024

Oct 20, 2024

Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 20, 2024

Oct 18, 2024

Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat

Oct 18, 2024

Oct 16, 2024

(APGE) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 16, 2024

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire

Oct 16, 2024

11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat

Oct 16, 2024

Oct 15, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat

Oct 15, 2024

Oct 14, 2024

Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 14, 2024

Oct 09, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat

Oct 09, 2024

Oct 08, 2024

Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily

Oct 08, 2024

Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 08, 2024

Oct 07, 2024